FDA Approves Psilocybin Study for the Treatment of Depression and Obsessive Compulsive Disorders
Over the years, the hallucinogenic mushroom has been shown to be effective in treating a variety of mental problems. The Food and Drug Administration American (FDA) now approves the use of its active ingredient, psilocybin. The result will be a COMPASS Pathways study, aimed at treating drug-resistant depression and obsessive-compulsive disorder.
The medicinal mushroom?
Magic mushrooms have been used in human society since the age of 9,000 years. Archaeological artifacts from the Stone Age indicate the use of mushrooms in Africa and Europe. These mushrooms, which contain the active ingredients psilocybin et psilocin, are not strangers to the study either. Since the last century, studies have been conducted on psilocybin. In particular, we recognize Timothy Leary's research at Harvard University in the 60 years.
The activity of magic mushrooms on the brain relieves mental states and even long-term behavioral changes. Thus, fungi contain psychoactive substances that "cap" receptors located at the ends of nerve cells in the brain. They are similar to serotonin.
In recent years, studies on these substances have begun to focus on mental illnesses and signs of improvement in the condition of patients with mental illness, such as depression, anxiety, obsessive-compulsive disorder (TOC) and a tendency to addiction. What currently interests the FDA. Moreover, other studies have shown that magic mushrooms can be effective by getting rid of addictions such as smoking and alcohol.
A study of 2014, consisted of brain fMRI scans on 15 treated people. They injected psilocybin, the active ingredient in magic mushrooms. And, brain tests were compared with those who received placebo.
More recently, Dr. Robin Carter Harris, a researcher at the Department of Neuroscience at Imperial College London, explains in his lecture that new electrical connections occur entirely in the brain under the influence of psilocybin. Then, she creates "new" feelings that we did not know before, such as hallucinations, ego breakdown, and various spiritual experiences.
The treatment of obsessive-compulsive disorder
Because of their "imitation" for neurotransmitters such as serotonin, the psychoactive substances contained in hallucinogenic mushrooms are involved in the treatment of our emotions and their ability to influence our perception. The psychedelic may therefore be useful for the treatment of psychiatric disorders. Indeed, scientists find that psilocybin has a positive effect on patients with depression, anxiety disorders and obsessive-compulsive disorder (OCD). These are all diseases very common in Western culture ...
London researchers have found the year, the immediacy of the effects. After treatment with psilocybin, patients experience an improvement in mood or relief of tension and anxiety.
"reset"And"Defrag" of the brain
MRI scans show a reduction in blood flow in the brain regions responsible for the treatment of emotions. Some patients use analogs from the computer world, such as "reset"For the brain or"Defrag"As for a hard drive ... Another Johns Hopkins University study reports even stronger results. Six months after treatment with psilocybin, 80% of subjects report definitive relief of symptoms of anxiety and depression.
An important benefit of magic mushrooms is that they act where standard drugs are unusable. In addition, you do not need to consume them for long (long term), to feel the effects ... They can therefore be a good substitute for those who are resistant to the most common antidepressants. The almost immediate effect (treatment in a few hours ...) can cure a deep anxiety. So to speak, the mushroom can reduce the fear of death , especially among terminally ill patients.
On the other hand, it is important to remember that these substances have not yet been studied in detail; but only in combination with another psychotherapy. However, there are also patients who have experienced adverse effects such as anxiety, high blood pressure, etc. But, the medical mushroom is currently considered the amazing, the safest he is not involved in the original disease
The FDA recently approved the use of psilocybin as part of a new COMPASS Pathways study. She will be examining 216 patients with trough not responding to existing medicines on the market (drug-resistant).